Investigational drug · Phase 3
JNJ-90301900
Also called: NBTXR3, Functionalized hafnium oxide nanoparticles
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "JNJ-90301900"
First trial start
2021
Dec 10, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-90301900", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Squamous Cell
- Carcinoma, Non-Small-Cell Lung
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-90301900" as an intervention, largest first.
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCPivotal-lookingRecruiting
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
NCT04892173 · 500 participants (planned) · Start Dec 10, 2021 · Primary completion Jun 30, 2028
Drug: JNJ-90301900 (NBTXR3); Cetuximab · For: Carcinoma, Squamous Cell
Sites: Birmingham, Alabama; Duarte, California; La Jolla, California · 196 sites in all
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
NCT06667908 · 130 participants (planned) · Start Dec 6, 2024 · Primary completion Dec 31, 2028
Drug: JNJ-90301900; Durvalumab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: La Jolla, California; Farmington, Connecticut; New Haven, Connecticut · 45 sites in all
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
NCT07219212 · 45 participants (planned) · Start Jan 26, 2026 · Primary completion Jul 14, 2028
Drug: JNJ-90301900; Cisplatin and 2 more · For: Squamous Cell Carcinoma of Head and Neck
Sites: Birmingham, Alabama; Duarte, California; La Jolla, California · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Nanocarrier design for lysosome-targeted ferroptosis induction in cancer therapy: from immune mechanisms to translational assessment.
Shin Y, Lee K, Kim G, et al. · Drug Deliv Transl Res 2026
- Comment on "Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma".
Khakimovna KA, Bakhodirjon S, Armstrong JJ · J Cancer Res Clin Oncol 2026
- Multifunctional nanoplatforms nanomedicine-device combination products: a translational maturity framework spanning nanocoated implants, theranostic platforms, wearable nanosensors, drug-eluting devices, intratumoral nanoparticle injections, and inorganic hybrid nanoplatforms.
Sahu A, Fatima S · Nanomedicine (Lond) 2026
- Nanoparticle radiosensitizers in cancer radiotherapy: bridging preclinical promise and clinical reality.
Piao Z, Piao Z, Zhang S · Clin Transl Oncol 2026
- Beyond apoptosis: nanomedicine enabled reprogramming of tumor cell death for next-generation radiosensitization.
Ye X, Tao Y, Min Y, et al. · J Nanobiotechnology 2026
- Multimodal synergistic effects and theranostic integration of hafnium-based nanoradiosensitizers for enhancing precision radiotherapy.
Chen Y, Zhou Z, Wang D, et al. · Biomaterials 2026
Also in development for Carcinoma, Squamous Cell
- N17350Phase 21 trial
Onchilles Pharma Inc · Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.